🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/02/2023 20,05 20,08 18,56 18,58 -8,52% 7,58% 886.000
17/02/2023 19,28 20,35 18,96 20,31 +5,23% 7,21% 853.300
16/02/2023 19,42 19,94 19,24 19,30 -1,78% 3,60% 729.200
15/02/2023 19,48 19,91 19,36 19,65 -0,46% 2,80% 524.400
14/02/2023 19,55 20,12 19,35 19,74 -0,90% 3,94% 509.000
13/02/2023 20,25 20,57 19,52 19,92 -1,04% 5,19% 551.400
10/02/2023 20,31 20,52 19,71 20,13 -1,37% 3,96% 565.300
09/02/2023 21,16 21,61 20,21 20,41 -1,31% 6,62% 538.700
08/02/2023 21,24 21,75 20,67 20,68 -3,09% 5,08% 453.000
07/02/2023 21,07 21,47 20,68 21,34 +1,28% 3,75% 563.400
06/02/2023 20,27 21,13 19,83 21,07 +2,73% 6,43% 785.700
03/02/2023 21,00 21,05 20,32 20,51 -3,07% 3,48% 838.200
02/02/2023 21,00 22,03 20,80 21,16 -5,41% 5,86% 1.645.600
01/02/2023 21,50 22,75 21,11 22,37 +3,42% 7,63% 912.800
31/01/2023 22,09 22,73 21,46 21,63 -3,22% 5,75% 956.000
30/01/2023 23,00 23,00 22,25 22,35 -3,37% 3,26% 728.700
27/01/2023 23,05 23,63 22,66 23,13 +0,17% 4,21% 965.900
26/01/2023 23,59 23,59 22,41 23,09 -0,26% 5,00% 596.200
25/01/2023 22,49 23,19 22,27 23,15 +1,45% 4,09% 1.037.100
24/01/2023 22,23 23,05 21,94 22,82 +3,63% 4,99% 814.400
23/01/2023 21,50 22,19 21,36 22,02 +3,57% 3,86% 1.162.200
20/01/2023 21,15 21,46 20,36 21,26 +1,77% 5,20% 988.500
19/01/2023 19,43 21,20 19,26 20,89 +7,35% 9,98% 1.545.400
18/01/2023 20,31 21,05 19,22 19,46 -4,19% 9,01% 911.100
17/01/2023 20,43 21,17 20,12 20,31 -0,34% 5,14% 1.587.200
13/01/2023 18,35 20,38 18,35 20,38 +9,69% 11,06% 1.591.800
12/01/2023 18,31 18,87 18,14 18,58 +0,87% 3,99% 1.160.200
11/01/2023 18,00 18,63 17,50 18,42 +1,21% 6,28% 1.136.600
10/01/2023 17,60 18,40 17,60 18,20 +3,94% 4,55% 1.416.500
09/01/2023 18,67 18,67 17,31 17,51 -5,25% 7,28% 1.595.100